Select Medical Holdings Corporation
$16.51-$0.02 (-0.1%)
Last close · Data as of Jun 30, 2026
- Market cap
- $2.0B
- P/E
- 14.0x
- EV / EBITDA
- 9.2x
- Revenue
- $5.5B
- Net margin
- 2.7%
- ROCE
- 6.9%
Price chart
Technical chartScreen technicals →Hidden because the last close is more than three trading days older than the latest prices of its class.
Daily closes.
Go deeper
Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes
Performance
Price return, before dividends, to the 30 Jun 2026 close.
- 1M
- Stale
- 3M
- Stale
- 6M
- Stale
- 1Y
- Stale
- 5Y
- Stale
- Hidden because the last close is more than three trading days older than the latest prices of its class.
52-week range
Day change -$0.02 (-0.1%) from $16.53 to $16.51 · Last close Jun 30, 2026
Best weekday to invest, historically
The same weekly amount in SEM, bought on each weekday since 2021.
News & filings
What Select Medical Holdings filed, who traded, and what's next
How to read this
"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.
AI Summary
US StockConcernReturn on equity of 8.6% against a peer median of 3.2%.
Strengths (1)
- Free cash flow was 0.80 times net profit in fiscal 2025.
- Prices are as of 30 Jun 2026; price-based points are paused until newer prices arrive.
Prices to the 30 Jun 2026 close · Financial year: fiscal 2025
Rule-based from financial data. Not advice.
About the company
Select Medical Holdings Corporation, through its subsidiaries, operates critical illness recovery hospitals, rehabilitation hospitals, and outpatient rehabilitation clinics in the United States.
Read moreShow less
Select Medical Holdings Corporation, through its subsidiaries, operates critical illness recovery hospitals, rehabilitation hospitals, and outpatient rehabilitation clinics in the United States. The Critical Illness Recovery Hospital segment consists of hospitals that provide services for heart failure, infectious disease, respiratory failure and pulmonary disease, surgery requiring prolonged recovery, renal disease, neurological events, and trauma. The Rehabilitation Hospital segment offers therapy and rehabilitation treatments, including rehabilitative services for brain and spinal cord injuries, strokes, amputations, neurological disorders, orthopedic conditions, pediatric congenital or acquired disabilities, and cancer. The Outpatient Rehabilitation segment operates rehabilitation clinics that provide physical, occupational, and speech rehabilitation programs and services; and specialized programs, such as functional programs for work related injuries, hand therapy, pelvic health rehabilitation, post-concussion rehabilitation, pediatric and cancer rehabilitation, and athletic training services. Select Medical Holdings Corporation was founded in 1996 and is headquartered in Mechanicsburg, Pennsylvania.
- Sector
- Healthcare
- Shares outstanding
- 126.1M
Key statistics
Screen fundamentals →Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.
Valuation
- Market cap
- $2.0B
- P/E
- 14.0x
- P/B
- 1.2x
- EV / EBITDA
- 9.2x
- EV / Sales
- 0.9x
- P/S
- 0.4x
- 52-week high
- $16.66
- 52-week low
- $11.77
Profitability
- Operating margin
- 6.2%
- Net margin
- 2.7%
- EBITDA margin
- 9.7%
- ROE
- 8.6%
- ROCE
- 6.9%
- ROA
- 2.5%
- Asset turnover
- 0.93
Growth
- RevenueFY2025, the latest fiscal year in the company's growth history.
- $5.5B
- Revenue growth, 1YFY2025, the latest fiscal year in the company's growth history.
- 5.1%
- Revenue CAGR, 3YFY2025, the latest fiscal year in the company's growth history.
- 5.8%
- Net profit growth, 1YFY2025, the latest fiscal year in the company's growth history.
- -31.7%
- Free cash flowFY2025, the latest fiscal year in the company's growth history.
- $117.2M
Solvency
- Current ratio
- 1.04
- Debt / Equity
- 1.68
- Debt / Assets
- 0.49
- CFO / Net profit
- 2.37
- Cash / Market cap
- 1.3%
Where the revenue went
Of every $100 of FY2025 revenue, $3 was left as net income.
| From | To | Amount |
|---|---|---|
| Revenue | Cost of revenue | $4.8B |
| Revenue | Gross profit | $629.3M |
| Gross profit | Selling, general and administrative | $154.4M |
| Gross profit | Other operating expenses | $138.7M |
| Gross profit | Operating income | $336.2M |
| Operating income | Pretax income | $272.8M |
| Operating income | Interest and other expense | $63.4M |
| Pretax income | Tax and other | $126.5M |
| Pretax income | Net income | $146.2M |
Revenue and net profit
Revenue grew 5.1% in FY2025; net profit is the dashed line.
| Date | Revenue | Net profit |
|---|---|---|
| FY2022 | $4.6B | $159.0M |
| FY2023 | $4.8B | $243.5M |
| FY2024 | $5.2B | $214.0M |
| FY2025 | $5.5B | $146.2M |
Cash flows
FY2025: $346.5M from operations, $117.2M free after investment (dashed).
| Date | Operating cash flow | Free cash flow |
|---|---|---|
| FY2022 | $284.8M | $94.5M |
| FY2023 | $582.1M | $352.9M |
| FY2024 | $517.9M | $295.7M |
| FY2025 | $346.5M | $117.2M |
Growth
Latest fiscal year 2025: each figure with its change over the year before.
- Revenue
- $5.5B+5.1%1Y
- EBITDA
- $531.0M+4.7%1Y
- Net profit
- $146.2M-31.7%1Y
- Cash from operations
- $346.5M-33.1%1Y
- Free cash flow
- $117.2M-60.3%1Y
- Revenue CAGR, 3Y
- 5.8%
- Net profit CAGR, 3Y
- -2.8%
| Year | Revenue | EBITDA | Net profit | FCF | ROE | Revenue growth 1Y | Net profit growth 1Y |
|---|---|---|---|---|---|---|---|
| FY2025 | $5.5B | $531.0M | $146.2M | $117.2M | 8.6% | +5.1% | -31.7% |
Monthly returns
Month-by-month returns of SEM across the years, with the seasonal pattern.
Balance sheet
What the company owns and owes at the end of FY2025.
| Line | FY2025 |
|---|---|
| Assets | $5.9B |
| Current assets | $1.0B |
| Non-current assets | $4.8B |
| Liabilities | $3.8B |
| Current liabilities | $984.5M |
| Non-current liabilities | $2.8B |
| Equity | $2.0B |
| Paid-in capital | $874.9M |
| Retained earnings | $837.0M |
| Minority interest | $330.2M |
Market cap against peers
8 peers: same sector, nearest by size.
Peers map
Healthcare companies placed by value, growth and quality; SEM highlighted.
P/E against peers
SEM trades at 14.0x earnings against a peer median of 4.7x (a 195% premium).
Not shown (no positive earnings and no EV / Sales): Supernus Pharmaceuticals, Inc., Acadia Healthcare Company, Inc., Neogen Corporation, Sarepta Therapeutics, Inc.
Peer comparison
Same-sector peers by market cap, with the median.
| Company | Market cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|
| Select Medical Holdings CorporationSEMthis companyP/E ↑ premium | $2.0B | 14.0x | 1.2x | 8.6% | 9.2x |
| Supernus Pharmaceuticals, Inc.SUPN | $2.6B | -67.3x | 2.4x | -3.6% | 58.9x |
| TransMedics Group, Inc.TMDX | $2.5B | 13.0x | 5.2x | 40.2% | 16.8x |
| Acadia Healthcare Company, Inc.ACHC | $2.3B | -2.1x | 1.2x | -56.6% | -6.5x |
| Prestige Consumer Healthcare Inc.PBH | $2.2B | 11.3x | 1.1x | 10.1% | 9.5x |
| LeMaitre Vascular, Inc.LMAT | $2.1B | 37.0x | 5.4x | 14.7% | 25.3x |
| Neogen CorporationNEOG | $2.0B | -1.8x | 1.0x | -52.7% | -2.9x |
| ADMA Biologics, Inc.ADMA | $1.8B | 12.6x | 3.9x | 30.8% | 9.3x |
| Sarepta Therapeutics, Inc.SRPT | $1.8B | -2.5x | 1.5x | -62.5% | -3.2x |
| Peer median | — | 4.7x | 2.0x | 3.2% | 9.4x |
Year-to-date ROI
SEM since 1 January, against earlier years.
Historical volatility
SEM's day-to-day swings over 30, 60 and 180 days.
Financial statements
Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.
Consolidated figures in USD, fiscal years, newest first.
Operating margin by fiscal year
| Date | Operating margin |
|---|---|
| FY2022 | 3.1% |
| FY2023 | 5.5% |
| FY2024 | 5.2% |
| FY2025 | 6.2% |
| Line | FY2025 |
|---|---|
| RevenueTotal Revenue | $5.5B |
| Cost of revenueCost Of Revenue | $4.8B |
| Gross profitGross Profit | $629.3M |
| Operating expensesOperating Expense | $293.1M |
| Selling, general and administrativeSelling General And Administration | $154.4M |
| Other operating expensesOther Operating Expenses | -$1.6M |
| Depreciation and amortisationDepreciation And Amortization In Income Statement | $140.3M |
| Depreciation, amortisation and depletionDepreciation Amortization Depletion Income Statement | $140.3M |
| Total expensesTotal Expenses | $5.1B |
| Operating incomeOperating Income | $336.2M |
| Interest and other | |
| Pretax incomePretax Income | $272.8M |
| TaxTax Provision | $58.2M |
| Net incomeNet Income | $146.2M |
| Per share | |
| Supplementary |
| Line | FY2025 |
|---|---|
| AssetsTotal Assets | $5.9B |
| Current assetsCurrent Assets | $1.0B |
| Non-current assetsTotal Non Current Assets | $4.8B |
| LiabilitiesTotal Liabilities Net Minority Interest | $3.8B |
| Current liabilitiesCurrent Liabilities | $984.5M |
| Non-current liabilitiesTotal Non Current Liabilities Net Minority Interest | $2.8B |
| EquityTotal Equity Gross Minority Interest | $2.0B |
| Supplementary | |
| Other lines |
| Line | FY2025 |
|---|---|
| Operating cash flowOperating Cash Flow | $346.5M |
| Cash from continuing operationsCash Flow From Continuing Operating Activities | $346.5M |
| Net income, continuing operationsNet Income From Continuing Operations | $214.5M |
| Depreciation and amortisationDepreciation And Amortization | $140.3M |
| Depreciation, amortisation and depletionDepreciation Amortization Depletion | $140.3M |
| Stock-based compensationStock Based Compensation | $16.7M |
| Deferred taxDeferred Tax | $30.6M |
| Deferred income taxDeferred Income Tax | $30.6M |
| Operating gains and lossesOperating Gains Losses | -$54.5M |
| Earnings losses from equity investmentsEarnings Losses From Equity Investments | -$54.5M |
| Provision and write off of assetsProvisionand Write Offof Assets | $2.4M |
| Change in working capitalChange In Working Capital | -$59.7M |
| Other non-cash itemsOther Non Cash Items | $3.1M |
| Dividend received (operating)Dividend Received Cfo | $53.0M |
| Investing cash flowInvesting Cash Flow | -$216.5M |
| Cash from continuing investingCash Flow From Continuing Investing Activities | -$216.5M |
| Capital expenditureCapital Expenditure | -$229.2M |
| Purchase of PP&EPurchase Of PPE | -$229.2M |
| Net PP&E purchases and salesNet PPE Purchase And Sale | -$229.2M |
| AcquisitionsPurchase Of Business | -$10.7M |
| Net acquisitions and disposalsNet Business Purchase And Sale | -$10.7M |
| Other investing changesNet Other Investing Changes | $23.4M |
| Financing cash flowFinancing Cash Flow | -$163.2M |
| Cash from continuing financingCash Flow From Continuing Financing Activities | -$163.2M |
| Debt issuedIssuance Of Debt | $1.4B |
| Debt repaidRepayment Of Debt | -$1.3B |
| Net debt issuedNet Issuance Payments Of Debt | $42.3M |
| Short-term debt issuedShort Term Debt Issuance | — |
| Short-term debt repaidShort Term Debt Payments | -$9.1M |
| Net short-term debt issuedNet Short Term Debt Issuance | -$9.1M |
| Long-term debt issuedLong Term Debt Issuance | $1.4B |
| Long-term debt repaidLong Term Debt Payments | -$1.3B |
| Net long-term debt issuedNet Long Term Debt Issuance | $51.4M |
| Shares issuedIssuance Of Capital Stock | $0.00 |
| Common stock issuedCommon Stock Issuance | $0.00 |
| Net common stock issuedNet Common Stock Issuance | -$100.1M |
| Common stock repurchasedCommon Stock Payments | -$100.1M |
| Share buybacksRepurchase Of Capital Stock | -$100.1M |
| Stock options exercisedProceeds From Stock Option Exercised | — |
| Dividends paidCash Dividends Paid | -$31.4M |
| Common dividends paidCommon Stock Dividend Paid | -$31.4M |
| Other financing chargesNet Other Financing Charges | -$74.0M |
| Change in cashChanges In Cash | -$33.2M |
| Cash at the start of the yearBeginning Cash Position | $59.7M |
| Cash at the end of the yearEnd Cash Position | $26.5M |
| Free cash flowFree Cash Flow | $117.2M |
| Supplemental |
Learn while you research
Academy chapters picked for Select Medical Holdings Corporation and the metrics on this page.
- 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
- 02 Leverage RatiosDebt/Equity of 1.68 is elevated, understand what that means for solvency.6 min read
- 03 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
- 04 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
- 05 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read